(Total Views: 786)
Posted On: 07/28/2020 12:43:48 AM
Post# of 153890
Excellent post, thanks for the info.
“The main challenge for this therapy is that antibody treatments will cause the virus to mutate and escape the antibody. REGN10933 and REGN10987 are antibodies that both target the spike protein but their binding domains do not overlap. Regeneron test tube experiments showed that the virus will quickly mutate and escape if you use only one antibody or if two antibodies with overlapping binding sites.”
Any chance you could provide a link for the first and last sentence of your paragraph?
“The main challenge for this therapy is that antibody treatments will cause the virus to mutate and escape the antibody. REGN10933 and REGN10987 are antibodies that both target the spike protein but their binding domains do not overlap. Regeneron test tube experiments showed that the virus will quickly mutate and escape if you use only one antibody or if two antibodies with overlapping binding sites.”
Any chance you could provide a link for the first and last sentence of your paragraph?
(0)
(0)
